This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richardson, D. C.
Right arrow Articles by Low, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richardson, D. C.
Right arrow Articles by Low, D. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1911-1914, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1911-1914.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae

David C. Richardson, Darrin Bast, Allison McGeer, and Donald E. Low*

Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Received 23 October 2000/Returned for modification 23 February 2001/Accepted 15 March 2001

To determine if susceptibility testing of Streptococcus pneumoniae could detect those isolates that had one of the recognized mechanisms of fluoroquinolone resistance, 101 isolates were selected; the levofloxacin MIC for 28 of these isolates was >= 4 µg/ml. Only isolates with both parC and gyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results. Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method.


* Corresponding author. Mailing address: Dept. of Microbiology, Mount Sinai Hospital, 600 University Ave., Rm. 1487, Toronto, Ontario M5G 1X5, Canada. Phone: (416) 586-4435. Fax: (416) 586-8746. E-mail: dlow{at}mtsinai.on.ca.


Antimicrobial Agents and Chemotherapy, June 2001, p. 1911-1914, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1911-1914.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Capoor, M. R., Rawat, D., Nair, D., Hasan, A. S., Deb, M., Aggarwal, P., Pillai, P. (2007). In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J Med Microbiol 56: 1490-1494 [Abstract] [Full Text]  
  • Dias, R., Louro, D., the Antimicrobial Resistance Surveillance Program, , Canica, M. (2006). Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Isolates in Portugal over an 11-Year Period.. Antimicrob. Agents Chemother. 50: 2098-2105 [Abstract] [Full Text]  
  • Decousser, J.-W., Methlouthi, I., Pina, P., Collignon, A., Allouch, P., on behalf of the ColBVH Study Group, (2006). New Real-Time PCR Assay Using Locked Nucleic Acid Probes To Assess Prevalence of ParC Mutations in Fluoroquinolone-Susceptible Streptococcus pneumoniae Isolates from France.. Antimicrob. Agents Chemother. 50: 1594-1598 [Abstract] [Full Text]  
  • Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
  • Powis, J., McGeer, A., Green, K., Vanderkooi, O., Weiss, K., Zhanel, G., Mazzulli, T., Kuhn, M., Church, D., Davidson, R., Forward, K., Hoban, D., Simor, A., Low, D. E. (2004). In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002. Antimicrob. Agents Chemother. 48: 3305-3311 [Abstract] [Full Text]  
  • Decousser, J.-W., Pina, P., Viguier, F., Picot, F., Courvalin, P., Allouch, P. (2004). Invasive Streptococcus pneumoniae in France: Antimicrobial Resistance, Serotype, and Molecular Epidemiology Findings from a Monthly National Study in 2000 to 2002. Antimicrob. Agents Chemother. 48: 3636-3639 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Ross, J. J., Worthington, M. G., Gorbach, S. L., Tillotson, G. S., Zhao, X., Drlica, K., Zhanel, G. G., Hoban, D. J., Chan, C. K., Hutchinson, J., Low, D. E., de Azavedo, J., Bast, D. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 347: 65-67 [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C.S., Kibsey, P., Fleming, C., Low, D. E. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 346: 747-750 [Full Text]  
  • Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A., Flamm, R., Doern, G. V. (2002). Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46: 680-688 [Abstract] [Full Text]